Tag
This study quantifies the risk and identifies predictors for systemic lupus erythematosus development in children presenting with skin-limited discoid lupus erythematosus, highlighting the importance of early monitoring especially in patien
A newly developed weighted flare scoring system in SLE accurately predicts organ damage accumulation, outperforming traditional flare classifications and informing treat-to-target strategies.
Dapirolizumab pegol, a CD40 ligand inhibitor, significantly improves disease activity in moderate-to-severe SLE over 48 weeks when added to standard care, supported by robust phase 3 trial data and pharmacokinetic findings.
Deucravacitinib, an oral selective TYK2 inhibitor, demonstrates significant suppression of interferon and B-cell pathway biomarkers in active SLE patients, supporting ongoing phase 3 trials for this challenging autoimmune disease.
In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and pla
This article reviews a pivotal phase 3 trial demonstrating telitacicept’s efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.
A phase 1 trial demonstrates that the allogeneic CD19-targeting T cell therapy YTS109 is safe and induces clinical remission, immune resetting, and renal tissue restoration in patients with refractory systemic lupus erythematosus complicate
A large Taiwanese cohort study links higher PM2.5 exposure to a more than threefold increased risk of developing systemic lupus erythematosus, underscoring the need for air quality policy interventions.
A 4-year phase 3 extension study shows that anifrolumab improves patient-reported outcomes and quality of life in systemic lupus erythematosus, with a favorable safety profile.
